Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzylpenicilloyl polylysine is a diagnostic agent used as a skin test antigen to assess sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected of having clinical penicillin hypersensitivity. It is a conjugate of the major antigenic determinant of penicillin (the benzylpenicilloyl group, which acts as a hapten) covalently bound to the carrier protein poly-L-lysine. When injected intradermally or subcutaneously, it reacts with specific IgE antibodies in sensitized individuals, triggering the release of chemical mediators and producing an immediate-type hypersensitivity reaction if present. This test helps identify patients at risk for allergic reactions to therapeutic doses of penicillin[1][2][3][4][5]. **Developers:** AllerQuest **Manufacturers:** AllerQuest, ALK-Abelló
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzylpenicilloyl polylysine.